Published in Virology on January 05, 2001
AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses (2010) 1.07
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol (2006) 1.05
Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention. AIDS Res Ther (2006) 0.96
Enhanced methamphetamine metabolism in rhesus macaque as compared with human: an analysis using a novel method of liquid chromatography with tandem mass spectrometry, kinetic study, and substrate docking. Drug Metab Dispos (2014) 0.81
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science (1993) 12.22
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science (1995) 9.48
pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell (1987) 9.29
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature (1986) 8.36
AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science (1986) 5.58
Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science (1996) 5.55
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol (1998) 5.05
Slow, persistent replication of lentiviruses: role of tissue macrophages and macrophage precursors in bone marrow. Proc Natl Acad Sci U S A (1985) 4.66
Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus. Science (1985) 4.31
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc (1997) 3.69
Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis (2001) 3.47
Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages. J Virol (1986) 3.45
Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res Hum Retroviruses (1998) 3.40
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol (2001) 3.40
Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques (1993) 3.36
Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification. Nat Med (1998) 3.19
Antigenic shift of visna virus in persistently infected sheep. Science (1977) 3.17
Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med (1972) 3.09
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother (1998) 3.01
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96
Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol (1998) 2.94
Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol (1982) 2.87
Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol (1996) 2.86
Selection of a fixative for identifying T cell subsets, B cells, and macrophages in paraffin-embedded mouse spleen. J Immunol Methods (1983) 2.82
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med (1999) 2.77
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
Force fluctuations in bead packs. Science (1995) 2.59
Activation of caprine arthritis-encephalitis virus expression during maturation of monocytes to macrophages. Infect Immun (1983) 2.52
Lentiviral diseases of sheep and goats: chronic pneumonia leukoencephalomyelitis and arthritis. Rev Infect Dis (1985) 2.51
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother (1998) 2.44
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med (2000) 2.33
Derivation of neurotropic simian immunodeficiency virus from exclusively lymphocytetropic parental virus: pathogenesis of infection in macaques. J Virol (1992) 2.30
Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol (2000) 2.24
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother (1996) 2.15
Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses (1997) 2.12
Behavioral disease in rats caused by immunopathological responses to persistent borna virus in the brain. Science (1983) 2.10
High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol (1999) 2.08
Genomic changes associated with antigenic variation of visna virus durig persistent infection. Proc Natl Acad Sci U S A (1980) 2.04
Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res Hum Retroviruses (1998) 1.97
Etiology of progressive multifocal leukoencephalopathy. Identification of papovavirus. N Engl J Med (1973) 1.90
Analysis of envelope changes acquired by SIVmac239 during neuroadaption in rhesus macaques. Virology (1993) 1.89
Studies of the antigenic relationships of the new human papovaviruses by electron microscopy agglutination. Infect Immun (1973) 1.84
Antigenic variation in visna virus. Cell (1979) 1.81
MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med (2001) 1.81
Virus mutation during 'slow infection': temporal development and characterization of mutants of visna virus recovered from sheep. J Gen Virol (1978) 1.80
Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein. J Biol Chem (1994) 1.79
Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol (2010) 1.78
Slow virus infection: replication and mechanisms of persistence of visna virus in sheep. J Infect Dis (1977) 1.78
cis- and trans-acting transcriptional regulation of visna virus. Science (1985) 1.74
Pathogenesis of SIVmac infection in Chinese and Indian rhesus macaques: effects of splenectomy on virus burden. Virology (1994) 1.73
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 1.72
The pathogenesis of viral leukoencephalomyelitis-arthritis of goats. I. Persistent viral infection with progressive pathologic changes. Lab Invest (1980) 1.72
The nucleic acid of an SV40-like virus isolated from a patient with progressive multifocal leukoencephalopathy. Virology (1973) 1.71
Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol (2000) 1.71
Pathogenesis of human poliovirus infection in mice. I. Clinical and pathological studies. J Neuropathol Exp Neurol (1980) 1.68
Pathogenesis of Borna disease in rats: immune-mediated viral ophthalmoencephalopathy causing blindness and behavioral abnormalities. J Infect Dis (1983) 1.66
A borna virus cDNA encoding a protein recognized by antibodies in humans with behavioral diseases. Science (1990) 1.63
COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer (2009) 1.62
Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol (2012) 1.62
A double labeling technique for performing immunocytochemistry and in situ hybridization in virus infected cell cultures and tissues. J Virol Methods (1985) 1.60
Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS (1998) 1.58
Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem (1995) 1.58
Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv Pharmacol (2000) 1.57
A new influenza A virus infection in turkeys II. A highly pathogenic variant, a/turkey/ontario 772/66. Can Vet J (1968) 1.54
Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob Agents Chemother (1993) 1.54
Pathogenesis of Borna disease in rats: evidence that intra-axonal spread is the major route for virus dissemination and the determinant for disease incubation. J Virol (1987) 1.53
Biological characterization of the virus causing leukoencephalitis and arthritis in goats. J Gen Virol (1980) 1.53
Age dependence of viral expression: comparative pathogenesis of two rodent-adapted strains of measles virus in mice. Infect Immun (1974) 1.51
Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction. AIDS (1993) 1.48
Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion. Proc Natl Acad Sci U S A (1991) 1.48
Efficiency of in situ hybridization as a function of probe size and fixation technique. J Virol Methods (1985) 1.47
Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication. J Virol (2000) 1.47
Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol (2000) 1.47
Restricted replication of lentiviruses. Visna viruses induce a unique interferon during interaction between lymphocytes and infected macrophages. J Exp Med (1985) 1.46
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses (1998) 1.46
Virus-induced abortion. Studies of equine herpesvirus 1 (abortion virus) in hamsters. Lab Invest (1975) 1.45
Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence. J Virol (1986) 1.45
In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45
Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol (2003) 1.45
The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study. AIDS (1990) 1.44
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol (1996) 1.44
Nef enhances human immunodeficiency virus replication and responsiveness to interleukin-2 in human lymphoid tissue ex vivo. J Virol (1999) 1.43
Papovavirus of JC type in progressive multifocal leukoencephalopathy. Rapid identification and subsequent isolation. Arch Neurol (1973) 1.43
HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. Proc Natl Acad Sci U S A (1998) 1.42
Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses (1995) 1.42